相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody-Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies
Tae H. Han et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody-Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
Dongwei Li et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Strategies to address drug interaction potential for antibody-drug conjugates in clinical development
Dan Lu et al.
BIOANALYSIS (2013)
Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper
Boris Gorovits et al.
BIOANALYSIS (2013)
Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics
Surinder Kaur et al.
BIOANALYSIS (2013)
Applications of minimal physiologically-based pharmacokinetic models
Yanguang Cao et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2012)
Pharmacokinetic Considerations for Antibody Drug Conjugates
Kedan Lin et al.
PHARMACEUTICAL RESEARCH (2012)
Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions
Trudy Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics
LM Berezhkovskiy
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution
P Poulin et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2002)
分享论文
